Pharmathene

A long awaited trial verdict for SIGA Technologies (NASDAQ: SIGA) is poised to be revealed in the coming weeks, as investors are eager to see whether the company will hold on to exclusive rights for its lead drug, ST-246. ST-246 is the world's first treatment for smallpox, a potential bioterrism...

Rodman & Renshaw has downgraded shares of PharmAthene, Inc. (NYSE: PIP) to Underperform from Market Perform, and has set a price target at $2.50. Rodman said that it believes the best-case scenario outcome of an ongoing lawsuit is already priced into the stock, adding that PharmAthene is more...

James Altucher has taken an interesting look at Pharmathene, Inc. (AMEX: PIP), a company he believes can go from its current price, $2.64, to $20 or higher. There are two reasons for his prediction. The first relates to a lawsuit against SIGA Technologies, Inc. (NASDAQ: SIGA), a company that was...